Last reviewed · How we verify

Lidocaine jelly

Mayo Clinic · FDA-approved active Small molecule Quality 2/100

Lidocaine jelly, marketed by Mayo Clinic, is an established anesthetic in the healthcare sector. A key strength is its patent protection, which extends to 2028, providing a barrier to generic competition. The primary risk is the eventual patent expiry in 2028, which could lead to increased market competition and revenue erosion.

At a glance

Generic nameLidocaine jelly
Also known aslidocaine
SponsorMayo Clinic
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: